Jan Lindebjerg

Jan Lindebjerg

Auto-generated profile, based on publicly available information

Jan Lindebjerg

Department of Pathology, Vejle Hospital, Vejle, Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
THTorben Hansen
Torben Hansen
FSFlemming Brandt Sørensen
Flemming Brandt Sørensen
JLJan Lindebjerg
Jan Lindebjerg
Anders JakobsenAnders Jakobsen
Anders Jakobsen
MicroRNA-126 is the only microRNA (miRNA) known to be endothelial cell-specific influencing angiogenesis in several ways. The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC).

13 February 2013 in European Journal of Radiology
Verified
Journal Article
Closed access
PDF file
Søren Rafael RafaelsenSøren Rafael Rafaelsen
Søren Rafael Rafaelsen
CVC. Vagn-Hansen
C. Vagn-Hansen
TST. Sørensen
T. Sørensen
JLJ. Lindebjerg
J. Lindebjerg
JPJ. Pløen
J. Pløen
Anders JakobsenAnders Jakobsen
Anders Jakobsen

1 November 2006 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
KSKaren-Lise Garm Spindler
Karen-Lise Garm Spindler
JLJan Lindebjerg
Jan Lindebjerg
JNJens Nederby Nielsen
Jens Nederby Nielsen
DODorte Aalund Olsen
Dorte Aalund Olsen
CBClaus Bisgård
Claus Bisgård
Anders JakobsenAnders Jakobsen
Anders Jakobsen
EGFR immunohistochemistry (IHC) status is not a reliable predictive marker for response to EGFR-targeted therapies. The present study compares the EGFR status at DNA, RNA and protein level. Blood samples, corresponding normal colon and colorectal cancer tissue were collected from 199 colorectal cancer (CRC) patients. EGFR status was evaluated by FISH analysis, real-time RT-PCR, ELISA and IHC. A polymorphism in the EGFR promoter was evaluated by PCR analysis. The EGFR levels by different methods were mutually compared. Seventy-eight percent of primary tumours and corresponding lymph nodes had equivalent EGFR status (28/34). There was a tendency to higher median protein level (by ELISA) in IHC positive patients compared to IHC negative patients (p=0.086). The median EGFR gene expression level was significantly lower in tumours than in the normal colon with no difference according to IHC status. No tumours had increased gene copy number by FISH. EGFR Sp1-216 polymorphism analysis showed a tendency for different EGFR tumour protein levels and gene expression levels according to the different genotypes. The results show a poor correlation between EGFR status at DNA, RNA and protein level. The predictive value of a combination of methods needs further evaluation in the clinical setting.

1 February 2011 in Cancer Genetics
Verified
Journal Article
Closed access
TDThomas Dyrsø
Thomas Dyrsø
JLJian Li
Jian Li
KWKai Wang
Kai Wang
JLJan Lindebjerg
Jan Lindebjerg
SKSteen Kølvraa
Steen Kølvraa
DCDorthe G. Crüger
Dorthe G. Crüger

19 July 2011 in Histopathology
Verified
Journal Article
Open access
JLJan Lindebjerg
Jan Lindebjerg
NHNiels Hansborg
Niels Hansborg
JPJohn Ploen
John Ploen
Søren Rafael RafaelsenSøren Rafael Rafaelsen
Søren Rafael Rafaelsen
JJJens Christian Riis Jorgensen
Jens Christian Riis Jorgensen
Anders JakobsenAnders Jakobsen
Anders Jakobsen
International audienceHigh dose chemoradiation is now considered standard treatment of locally advanced rectal cancer. To provide feedback on the effect of this treatment, several regression grading systems have been proposed. For a grading system to be useful it has to be reproducible. The aim of this study was to test the reproducibility of a five point grading system, originally proposed by Mandard, and to describe the sources of disagreement. Tumor regression was assessed independently by two observers on 100 consecutive chemo radiated rectal cancer specimens. The grading system was very reproducible with weighted and unweighted kappa values of 0,89 and 0,82 respectively. The most frequent source of disagreement was assessment of the relative amount of fibrosis. Displacement of epithelium was a minor source

25 March 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KSKaren-Lise G Spindler
Karen-Lise G Spindler
NPNiels Pallisgaard
Niels Pallisgaard
JLJan Lindebjerg
Jan Lindebjerg
SFSanne K Frifeldt
Sanne K Frifeldt
Anders JakobsenAnders Jakobsen
Anders Jakobsen
As supplement to KRAS mutational analysis, BRAF and PIK3CA mutations as well as expression of PTEN may account for additional non-responders to anti-EGFR-MoAbs treatment. The aim of the present study was to investigate the utility as biomarkers of these mutations in a uniform cohort of patients with metastatic colorectal cancer treated with third-line cetuximab/irinotecan.